The development of combination antiretroviral therapy with human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors and protease inhibitors has provided a clinically effective method of suppressing viral load in HIV-1-infected individuals, and has resulted in dramatic reductions in HIV-associated morbidity and mortality. 1) However, no current therapies are curative, 2) and HIV-1 replicates again rapidly when treatment ceases.
3) The complexity of the dosing regimens and the toxicity of the current anti-HIV-1 therapy make it difficult to maintain patient compliance. 4) In addition, resistance to the currently available drugs is increasing. 5) Therefore, there remains a need to identify new classes of agents with improved efficacy and less toxicity.
The process of HIV-1 entry into host cells is one of the attractive targets for inhibition of HIV-1 replication. 6 ) Recent successful studies with enfuvirtide (T-20), a peptide inhibitor of gp41-mediated HIV-1 entry, have confirmed this process as a clinically relevant target. 7) It has been reported that HIV-1 strains that cause the initial infection predominantly utilize CC chemokine receptor 5 (CCR5) as a coreceptor. 8) CCR5-using (R5) HIV-1 is isolated exclusively during the asymptomatic stage, which usually persists for 5 to 10 years. 9) CCR5 is a member of the seven-transmembrane G protein-coupled receptor superfamily.
10) The natural ligands for CCR5 are the CC chemokines [regulated on activation, normal T cell expressed and secreted (RANTES), macrophage inflammatory protein 1a (MIP-1a), and MIP-1b], which have been reported to inhibit R5 HIV-1 infection in vitro. 11) Individuals homozygous for a defect in CCR5 expression have been identified as being highly resistant to HIV-1 infection, while this defect does not cause a significant health problem. [12] [13] [14] In addition, infected individuals heterozygous for the defective gene appear to exhibit delayed disease progression. 15) These observations suggest that appropriate, small-molecule CCR5 antagonists functioning as HIV-1 entry inhibitors could be promising anti-HIV-1 therapeutic agents.
Several research groups have reported structurally diverse CCR5 antagonists. [16] [17] [18] [19] [20] [21] [22] Our laboratories have previously described the discovery of TAK-779, an anilide derivative with a quaternary ammonium moiety, as a small-molecule CCR5 antagonist. 23, 24) Continued screening of Takeda compound libraries using [
I]RANTES and Chinese hamster ovary (CHO) cells expressing human CCR5 has now identified a novel lead compound, N-{3-[4-(4-fluorobenzoyl)piperidin-1-
yl]propyl}-1-methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (1), as a CCR5 antagonist (Fig. 1) . In this paper, we describe the discovery of the lead compound and the subsequent optimization, focused on a series of 5-oxopyrrolidine-3-carboxamides, to obtain potent CCR5 antagonists which can inhibit the HIV-1 cell entry.
Chemistry
Target compounds were prepared by two general methods as outlined in Charts 2 and 3. The first method (Chart 2) was utilized to investigate structure-activity relationships (SARs) of alkyl linker length (Fig. 1, C) and piperidine moiety modifications ( Fig. 1, D) . The starting carboxylic acid 2a was prepared by condensation of itaconic acid and methylamine (Chart 1). 25) Coupling of the carboxylic acid 2a with aniline using 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) gave anilide 3. Treatment of 3 with sodium hydride followed by the appropriate bromochloroalkane produced chlorides 4a-c. The 2-chloroethyl derivative 4d was prepared in a different manner as follows. N-Alkylation of the anilide 3 with ethyl bromoacetate followed by hydrolysis gave the carboxylic acid. The reduction of the mixed anhydride of the acid gave the alcohol, which on reaction with carbon tetrachloride and triphenylphosphine yielded 4d. October 24, 2003 potassium iodide and potassium carbonate to provide the target compounds 5a-i. Alternatively, compounds 7a-e were obtained by reductive amination of aldehyde 6 with amines using sodium triacetoxyborohydride. The aldehyde 6 was prepared from the anilide 3 by N-alkylation with 2-(2-bromoethyl)-1,3-dioxolane followed by hydrolysis with hydrochloric acid. Benzoylpiperazine derivative 5j was prepared by hydrogenolysis of benzylpiperazine 5i followed by benzoylation.
In order to explore the effect of substitutions on the central phenyl ring (Fig. 1, B) and 5-oxopyrrolidine moiety (Fig. 1,  A 26) which were converted to amine derivatives 9a-t by reductive amination with various aryl or aralkyl amines using sodium triacetoxyborohydride. Coupling reactions of the amines 9a-q, s, t with 5-oxopyrrolidine-3-carboxylic acids 2a-n were carried out via the corresponding acid chlorides to afford the targets 10a-p, 11a, b, 12a-m, 15a, b. Compound 10q was prepared by the carbodiimide-mediated coupling of the amine 9r with the acid 2a. The carboxylic acids 2b-n were prepared by literature methods 25) from the corresponding amines (Chart 1). Removal of the 2,4-dimethoxybenzyl group of compound 12m with trifluoroacetic acid (TFA) gave compound 13, which on N-alkylation led to compound 14a, b.
All compounds described were prepared and tested as racemates.
Results and Discussion
The lead compound 1 was discovered by high-throughput screening of Takeda compound libraries using a binding assay based on [ 125 I]RANTES and CHO cells expressing human CCR5. This compound was shown to have moderate affinity for CCR5 with an IC 50 value of 1.9 mM. Our initial goal was to improve the CCR5 binding affinity. The structural feature of the lead compound 1 is 5-oxopyrrolidine-3-carboxamide moiety. Deletion of the entire 5-oxopyrrolidin-3-ylcarbonyl group, as in the intermediates 9, resulted in complete loss of activity, suggesting that this moiety was required for interaction with CCR5. Therefore, our initial SAR studies were focused on a series of 5-oxopyrrolidine-3-carboxamides.
The lead compound 1 could be divided into four subunits ( Fig. 1) : 5-oxopyrrolidine substituent (A), central phenyl ring (B), alkyl linker (C), and piperidine moiety (D). We first modified the alkyl linker (C) length in order to optimize the spacing between the two halves of the molecule. As shown in Table 1 , the lead compound 1 with a three-carbon chain showed the best activity. Shortening the chain of 1 to two carbons caused a marked decrease in potency (5c), while lengthening it led to a more gradual loss of affinity, compound 5a and 5b being ca. 2 and 3 times less potent than 1, respectively.
With the SAR on the chain established, we then varied the piperidine moiety (D) to investigate the role of the piperidine ring and the substituent at the 4-position of the piperidine ( Table 2) . Replacement of the 4-fluorobenzoyl group in 1 with a 4-fluorobenzyl group showed a 6-fold enhancement in potency (11a, IC 50 ϭ0.31 mM), suggesting that the carbonyl group in the lead compound 1 was not necessary for CCR5 binding. The compound 5h (IC 50 ϭ0.48 mM) having a benzyl group also exhibited improved activity comparable to 11a. Removal of the benzyl group in 5h resulted in a large decrease in potency (5d), indicating that the benzene ring was essential for potent CCR5 binding affinity. Decreasing the distance from the piperidine ring to the benzene ring (5e) resulted in a loss of potency, as did increasing the distance (7c). Constraint of the benzene ring by introduction of a double bond (7a) or a spiro structure (5g) did not improve activity. Substitution with other groups such as a phenoxy (7d) or benzyloxy (7e) provided no improvement in binding affinity. Replacement of the basic piperidine with a less basic piperazine failed to maintain activity (5i, j). Since the 4-benzylpiperidine derivatives (5h, 11a) had an improved potency compared to the lead 1, this component was utilized for further exploration.
We next turned our attention to modification of the central phenyl ring (B) ( Table 3 ). Introduction of a methyl group at the 3-or 4-position of the phenyl ring resulted in a 3-or 5-fold improvement in the binding potency (10b, 10c), while the 2-methyl derivative 10a showed lower potency than the unsubstituted compound 5h. The activity of 4-tert-butyl compound 10d was better than 5h. 3,4-Disubstitution as in indan-5-yl derivative 10e also increased affinity compared to 5h. When the electron-donating methoxy group was introduced at the 4-position of the phenyl ring (10f), 3-fold reduction in potency was observed. Substitution at the 4-position of the phenyl ring with electron-withdrawing groups such as trifluoromethyl (10m) and cyano (10p) also lowered potency.
Moving the trifluoromethyl group to the 3-position of the phenyl ring (10l) restored binding potency comparable to that of 5h, while the bis-trifluoromethyl derivative 10n showed lower potency. The 3-cyano compound 10o was a poorer inhibitor, indicating that this moiety does not prefer polar substituents.
When a chlorine atom was introduced at the 4-position of the phenyl (10h), lower potency than the unsubstituted compound 5h was observed, but the 3-chloro derivative 10g exhibited 4-fold improvement in the binding affinity over 5h. Furthermore, the 3,4-dichlorinated derivative 10i was found to show 8-fold enhancement in inhibitory effect compared to 5h with an IC 50 value of 0.057 mM. Fluorinated (R 4 ϭF) analogue of 10i also showed good activity (11b, IC 50 ϭ 0.050 mM). Replacement of the 3,4-dichloro group by 3-chloro-4-fluoro (10j) or 3,4-difluoro (10k) group decreased the activity. Extension of the phenyl ring by a methylene unit IC 50 (mM)
was tolerated as seen with the benzyl derivative 10q. While studying the central phenyl fragment, we simultaneously investigated substitutions at the 1-position of the 5-oxopyrrolidine moiety (A) ( Table 4 ). Removal of the 1-methyl group led to compound 13, which was equipotent with the 1-methyl derivative 5h. Replacing the methyl group by a butyl (12a) provided a 4-fold increase in potency, and replacing by a 2,2,2-trifluoroethyl group (14a) showed a 6-fold improvement. These results led us to explore introduction of more bulky substituents to increase potency. The 1-benzyl derivative 12e (IC 50 ϭ0.038 mM) showed Ͼ10-fold enhancement in potency, whereas the 1-phenyl derivative 12d exhibited comparable activity to the 1-methyl derivative (5h). Extension of the benzyl as a phenylethyl (12j) showed similar potency compared to phenyl (12d), indicating the benzyl substituent (12e) was optimal for CCR5 binding. Saturation of the benzene ring in 12e affording 12c resulted in a loss of potency, suggesting that the aromatic ring was necessary for potent activity.
Substitution on the benzyl group was then investigated. Introduction of a chlorine atom at the 2-position of the benzyl was found to be tolerated (12f), while 3-or 4-chloro derivatives (12g, h) showed lower potency than the unsubstituted compound 12e. A similar trend was observed for methyl substituted analogues (12i, 14b). Replacement of the benzyl with a furan-2-ylmethyl (12k) led to a moderate loss in binding, while the pyridin-4-ylmethyl analogue (12l) resulted in 6-fold reduction of activity.
The previously discussed SAR of substitutions on the central phenyl ring of the 1-methyl-5-oxopyrrolidine derivatives (Table 3 ) was then applied to the 1-benzyl analogues. In the case of the 1-benzyl-5-oxopyrrolidine derivatives, introduction of 3-chloro (15a) or 3,4-dichloro (15b) substituents did not significantly change the activity.
On the basis of NMR analysis, we speculated about the required conformation of the 5-oxopyrrolidine-3-carboxamide derivatives for CCR5 binding. The synthesized compounds have a central N,N-disubstituted amide moiety as a structural feature. It has been known that N-methylanilides prefer the E form in which the phenyl ring is trans to the amide oxygen. 27, 28) In the E form, the plane of the phenyl ring is almost perpendicular to the amide plane. The 1 H-NMR analysis of the N-phenyl derivatives in this study revealed that most of the derivatives exist as an almost single rotameric form in solution at room temperature. The conformation of 10i (free base) was determined by a NOESY experiment in CDCl 3 at 300 K (Fig. 2 ). H-a (d 3.04) was found to correlate with H-b (d 7.30) and H-c (d 7.02) in the NOESY spectrum, whereas no cross peak was observed between H-a and H-d (d 3.69). These results suggested that 10i and probably other N-phenyl derivatives have an E form in solution. The preference of the E form in this series might contribute to the receptor binding.
Finally, the activities of selected compounds for inhibition of HIV-1 cell entry were examined by a HIV-1 envelope-mediated membrane fusion assay using R5 HIV-1 (JR-FL strain) envelope-expressing COS-7 cells and CCR5-expressing MOLT-4 cells. The most potent CCR5 antagonists 10i, 11b, 66 Vol. 52, No. 1 and 12e inhibited the membrane fusion with IC 50 values of 0.44, 0.19, and 0.49 mM, respectively. These results demonstrated that the 5-oxopyrrolidine-3-carboxamide derivatives could block R5 HIV-1 cell entry by preventing the binding of the R5 HIV-1 envelope to CCR5. The selectivity profile of compound 11b for other chemokine receptors was evaluated using a binding assay. The IC 50 values for CCR1, CCR2, CCR4, and CCR7 were all greater than 3 mM.
Conclusion
We have succeeded in the identification of a novel lead compound as a small-molecule CCR5 antagonist through high-throughput screening. The original lead 1 inhibited the binding of [
125 I]RANTES to CCR5 with an IC 50 value of 1.9 mM. Systematic modification of the lead 1, focused on a series of 5-oxopyrrolidine-3-carboxamides, resulted in the identification of compounds with improved binding affinity. The most potent CCR5 antagonists 10i (IC 50 ϭ0.057 mM), 11b (IC 50 ϭ0.050 mM), and 12e (IC 50 ϭ0.038 mM) inhibited HIV-1 envelope-mediated membrane fusion with IC 50 values of 0.44, 0.19, and 0.49 mM, respectively. Further efforts directed toward additional improvement of potency will be reported in due course.
Experimental
Reagents and solvents were used as obtained from commercial suppliers without further purification. Column chromatography was carried out on Merck silica gel 60 (230-400 mesh) or ICN basic alumina (activity III). The yields reported were not optimized. Melting points were determined on a Yanagimoto micro melting point apparatus and are uncorrected.
1 H-NMR spectra were recorded on a Varian Gemini 200 (200 MHz) spectrometer. Two-dimensional NOESY spectra were recorded on a Bruker DMX 600 (600 MHz) spectrometer. Chemical shifts are given in ppm with tetramethylsilane (organic solvents) or 3-(trimethylsilyl)propionic-2,2,3,3-d 4 acid, sodium salt (D 2 O) as an internal standard, and coupling constants (J) are given in hertz (Hz). Mass spectra were recorded using an LC/MS system consisting of a Hewlett-Packard 1100 HPLC instrument and a Waters ZMD mass detector (ESI positive). Compound purity was checked by elemental analysis or analytical HPLC. Elemental analyses were carried out by Takeda Analytical Laboratories Ltd. Analytical HPLC was performed on a Shimadzu LC-10A system using a Shiseido CAPCELL PAK C18 UG120 column (2.0ϫ50 mm, 3 mM). Chromatographic conditions were as follows: mobile phases, Aϭ0.1% TFA/H 2 O, Bϭ0.1% TFA/MeCN; gradient (A/B), 0 min (90/10), 4 min (5/95), 5.5 min (5/95), 5.51 min (90/10), 8 min (90/10); flow rate, 0.5 ml/min; detection, UV 220 nm. Retention times (t R ) and purity (area percent) are reported.
5-Oxopyrrolidine-3-carboxylic Acids (2a-n) Compounds 2a-n were prepared according to literature procedures. 25 25 g, 90 mmol) , and the mixture was stirred at room temperature for 4 h. The mixture was concentrated in vacuo, diluted with saturated aqueous NaHCO 3 (120 ml), and extracted with dichloromethane (DCM) (5ϫ120 ml). The organic layer was dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 9/1) to afford 3 (11.04 g, yield 84%) as a white solid, mp 163-165°C. 1 
N-(3-Chloropropyl)-1-methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (4a)
To an ice-cooled stirred solution of 3 (2.00 g, 9.2 mmol) in DMF (20 ml) was added NaH (60% in oil, 733 mg, 18 mmol). After 1 h the mixture was treated with 1-bromo-3-chloropropane (1.81 ml, 18 mmol), stirred for 30 min, removed from the ice bath, and stirred for an additional 1 h. The mixture was diluted with water (100 ml) and extracted with EtOAc (3ϫ50 ml). The organic layer was dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 9/1) to afford 4a (2.43 g, yield 90%) as a colorless oil. 1 The following compounds 4b, c were prepared using a procedure similar to that described for 4a from the corresponding bromochloroalkanes.
N-(4-Chlorobutyl)-1-methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (4b)
Yield 96%, oil. 
N-(2-Chloroethyl)-1-methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide (4d). Step 1: Ethyl 2-{[(1-Methyl-5-oxopyrrolidin-3-yl)carbonyl]-anilino}acetate
To an ice-cooled stirred solution of 3 (2.00 g, 9.2 mmol) in DMF (20 ml) was added NaH (60% in oil, 916 mg, 23 mmol). After 1 h the mixture was treated with ethyl bromoacetate (3.05 ml, 28 mmol), stirred for 30 min, removed from the ice bath, and stirred for an additional 6 h. The mixture was poured into ice-cooled 0.5 N HCl (100 ml) and extracted with EtOAc (3ϫ50 ml). The organic layer was dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 95/5) to afford the product (2.43 g, yield 87%) as a white solid, mp 72-74°C. 1 Step 2: 2-{[(1-Methyl-5-oxopyrrolidin-3-yl)carbonyl]anilino}acetic Acid To a stirred solution of the product from step 1 (1.83 g, 6.0 mmol) in MeOH (20 ml) was added 8 N NaOH (1.5 ml), and the mixture was stirred at room temperature for 10 h. The mixture was treated with 1 N HCl (13 ml) and concentrated in vacuo. The residue was dissolved in EtOAc, dried (MgSO 4 ), filtered, and concentrated in vacuo to give the product (1.54 g, yield 93%). Step 3: N-(2-Hydroxyethyl)-1-methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide To a stirred solution of the product from step 2 (829 mg, 3.0 mmol) and Et 3 N (627 ml, 4.5 mmol) in THF (15 ml) at Ϫ15°C was added ethyl chloroformate (430 ml, 4.5 mmol), and the mixture was stirred at from Ϫ15 to Ϫ10°C for 30 min. Then, a solution of NaBH 4 (227 mg, 6.0 mmol) in water (1.5 ml) was added at Ϫ10°C, and the mixture was stirred at from Ϫ10 to 0°C for 1 h. The mixture was treated with 1 N HCl at 0°C, and the organic solvent was removed in vacuo. The residue was extracted with DCM, and the organic layer was dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 95/5) to afford the product (662 mg, yield 84%) as a colorless oil. 1 Step 4: N-(2-Chloroethyl)-N-phenyl-1-methyl-5-oxo-3-pyrrolidinecarboxamide (4d) A mixture of the product from step 3 (659 mg, 2.5 mmol), triphenylphosphine (857 mg, 3.3 mmol), and carbon tetrachloride (10 ml) was stirred at reflux for 1 h. After cooling, the insoluble materials were removed by filtration. The filtrate was concentrated in vacuo, and the residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 95/5) to give an oil which solidified. The solid was triturated with Et 2 O and filtered to afford 4d (366 mg, yield 52%) as a slightly brown solid, which was used immediately in the subsequent reaction. 1 The following compounds 5a-g, i were prepared using a procedure similar to that described for 5h from the chlorides 4a-d and the corresponding amines.
N-{4-[4-(4-Fluorobenzoyl)piperidin-1-yl]butyl}-1-methyl-5-oxo-Nphenylpyrrolidine-3-carboxamide Fumarate (5a) Compound 5a was prepared from 4b and 4-(4-fluorobenzoyl)piperidine hydrochloride 31) in 80% yield, amorphous solid. Step 2: N-[3-(4-Benzoylpiperazin-1-yl)propyl]-1-methyl-5-oxo-Nphenylpyrrolidine-3-carboxamide Fumarate (5j) To an ice-cooled stirred solution of the product from step 1 (192 mg, 0.56 mmol) and Et 3 N (101 ml, 0.72 mmol) in THF (5 ml) was added benzoyl chloride (78 ml, 0.67 mmol), and the mixture was stirred for 1 h. The mixture was concentrated in vacuo, diluted with saturated aqueous NaHCO 3 (15 ml), and extracted with EtOAc (3ϫ30 ml). The organic layer was dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 4/1) to afford the free base (221 mg, 0.49 mmol) as an oil, which was treated with fumaric acid (57 mg, 0.49 mmol) to yield 5j (228 mg, yield 72%) as an amorphous solid. To an ice-cooled stirred solution of 3 (2.40 g, 11 mmol) in DMF (22 ml) was added NaH (60% in oil, 880 mg, 22 mmol). After 1 h the mixture was treated with 2-(2-bromoethyl)-1,3-dioxolane (2.58 ml, 22 mmol) and stirred at 80°C for 12 h. The mixture was concentrated in vacuo, diluted with water (45 ml), and extracted with DCM (3ϫ45 ml). The organic layer was dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 9/1) followed by crystallization from i-Pr 2 O/EtOAc to give the product (2.47 g, yield 70%) as a white solid., mp 108-110°C. 1 1H, t, Jϭ4.4 Hz), 7.15-7.25 (2H, m), 7.35-7.55 (3H, m) .
Step 2: 1-Methyl-5-oxo-N-(3-oxopropyl)-N-phenylpyrrolidine-3-carboxamide (6) The product from step 1 (1.95 g, 6.1 mmol) was dissolved in 1 N HCl (10 ml), and the mixture was stirred at room temperature for 18 h. The mixture was extracted with DCM (3ϫ20 ml), and the organic layer was dried (MgSO 4 -1-yl) propyl]-1-methyl-5-oxo-N-phenylpyrrolidine-3-carboxamide Hydrochloride (7a) To a stirred mixture of 6 (274 mg, 1.0 mmol), 4-benzylidenepiperidine hydrochloride 33) (231 mg, 1.1 mmol) in THF (10 ml) was added Et 3 N (209 ml, 1.5 mmol) followed by NaBH(OAc) 3 (318 mg, 1.5 mmol), and the mixture was stirred at room temperature for 6 h. The mixture was diluted with saturated aqueous NaHCO 3 (15 ml) followed by water (10 ml) and extracted with EtOAc (3ϫ20 ml). The organic layer was dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 6/1) to afford an oil (376 mg). The following compounds 7b-e were prepared using a procedure similar to that described for 7a from the corresponding amines. ) and DBU (30 ml, 0.2 mmol) in THF (40 ml) was added dropwise a solution of acrolein (90%, 1.49 ml, 20 mmol) in THF (5 ml) at Ϫ20°C, and the mixture was stirred at Ϫ20 to Ϫ10°C for 1 h. The mixture was treated with p-toluidine (2.14 g, 20 mmol) followed by NaBH(OAc) 3 (8. 48 g, 40 mmol) at Ϫ10°C and allowed to warm to room temperature. After 23 h, the mixture was diluted with aqueous NaHCO 3 and extracted with EtOAc. The organic layer was dried (MgSO 4 ), filtered, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc/MeOH 1/0 to 4/1) to afford the free base of 9d (4.07 g) as an oil. The following compounds 9a-c, e-t were prepared using a procedure similar to that described for 9d from piperidines 8a, b 36) 
N-{3-[4-(Diphenylmethyl)piperidin-1-yl]propyl}-1-methyl-5-oxo-N-

